Cadena Anthony M, Flynn JoAnne L, Fortune Sarah M
Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA Immunology Graduate program, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
mBio. 2016 Apr 5;7(2):e00342-16. doi: 10.1128/mBio.00342-16.
Tuberculosis remains a major health threat in much of the world. New vaccines against Mycobacterium tuberculosis are essential for preventing infection, disease, and transmission. However, the host immune responses that need to be induced by an effective vaccine remain unclear. Increasingly, it has become clear that early events in infection are of major importance in the eventual outcome of the infection. Studying such events in humans is challenging, as they occur within the lung and thoracic lymph nodes, and any clinical signs of early infection are relatively nonspecific. Nonetheless, clinical studies and animal models of tuberculosis have provided new insights into the local events that occur in the first few weeks of tuberculosis. Development of an effective vaccine requires a clear understanding of the successful (and detrimental) early host responses against M. tuberculosis, with the goal to improve upon natural immune responses and prevent infection or disease.
在世界上许多地区,结核病仍然是一个重大的健康威胁。新型抗结核分枝杆菌疫苗对于预防感染、疾病和传播至关重要。然而,有效疫苗需要诱导的宿主免疫反应仍不清楚。越来越明显的是,感染早期事件对感染的最终结果至关重要。在人类中研究此类事件具有挑战性,因为它们发生在肺部和胸内淋巴结,而且早期感染的任何临床症状都相对缺乏特异性。尽管如此,结核病的临床研究和动物模型为结核病最初几周内发生的局部事件提供了新的见解。开发有效疫苗需要清楚了解宿主针对结核分枝杆菌的成功(和有害)早期反应,目标是改善自然免疫反应并预防感染或疾病。